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Our long-standing evolutionary association with gut-associated microbial communities has given rise to an
intimate relationship, which affects many aspects of human health. Recent studies on the mechanisms that
link these microbial communities to immune education, nutrition, and protection against pathogens point
to microbiota-derived metabolites as key players during these microbe-host interactions. A disruption of
gut-associated microbial communities by antibiotic treatment can result in a depletion of microbiota-derived
metabolites, thereby enhancing pathogen susceptibility, impairing immune homeostasis, and contributing
to the rise of certain chronic inflammatory diseases. Here, we highlight some of the recently elucidatedmech-
anisms that showcase the impacts of microbiota-derived metabolites on human health.Introduction
The large intestine is host to a diverse microbial community, the
gut microbiota, which is composed predominantly of obligate
anaerobic bacteria. Bifidobacterium species, which belong to
the phylum Actinobacteria, dominate gut-associated microbial
communities within the first year of life in breast-fed infants.
This preponderance of Bifidobacterium species is explained by
their capability to break down milk oligosaccharides, constitu-
ents of milk that cannot be utilized by newborns for nutrition
but instead serve to guide the composition of the developing
infant gut microbiota (reviewed in Garrido et al., 2013). After
weaning, bacteria belonging to the phyla Bacteroidetes and
Firmicutes rise to dominance, while members of the phyla
Actinobacteria, and Proteobacteria are minor constituents
commonly found within a balanced community (Eckburg et al.,
2005; Koenig et al., 2011; Palmer et al., 2007). Occasionally rep-
resentatives of Fusobacteria, Verrucomicrobia, Cyanobacteria,
or other phyla can be present within the community. The com-
bined metabolic activities and host interactions of a balanced
gut-associated microbial community confer benefit to the host
by providing nutrition, protection against enteric pathogens,
and immune education. However, the mechanisms responsible
for the beneficial properties of a balanced microbial community
and some consequences of its interaction with the host immune
system are just beginning to be worked out. Here we will review
recent mechanistic insights into the benefits conferred by gut-
associated microbial communities on the immune system and
the adverse effects associated with their disruption by antibiotic
treatment.
Delivering the Goods: Microbiota-Derived Metabolites
Gut-associated microbial communities are highly diverse, vary
between individuals on the species level, and can change in
composition over time (reviewed in Lozupone et al., 2012), which
makes it unlikely that their health benefits can be reduced to the
presence of individual bacterial species within the community
alone. More likely, the beneficial properties of the gut microbiota
in the large bowel are attributable to its combined metabolic156 Cell Host & Microbe 16, August 13, 2014 ª2014 Elsevier Inc.activities and products, which are not immediately obvious
from an analysis of its composition by sequencing 16S RNA
genes. Thus, to understand how the gut microbiota affects
health it is important to know which products and metabolites
this community generates.
The gut microbiota can influence host responses by gener-
ating an abundance of microbe-specific molecules in the distal
gut. Some of these molecules, termed pathogen-associated
molecular patterns (PAMPs), are evolutionarily conserved and
are used by the host’s innate immune system to distinguish
microbes from self (Janeway, 1989). Although the name implies
an association with pathogens, all microbes produce PAMPs,
regardless of their pathogenic potential. We will thus refer to
PAMPs as conserved microorganism-associated molecular
patterns (MAMPs) throughout this review. As outlined below,
flagella, produced by motile bacterial species (Figure 1), and
certain polysaccharides covering the bacterial surface appear
to be MAMPs that are particularly important for interactions
between the host and its gut microbiota.
In addition to producing MAMPs, the fermentative growth of
microbes in the lower gastrointestinal tract generates amultitude
of metabolic end products. Complex carbohydrates and pro-
teins that cannot be degraded by the host enter the large bowel,
where they support growth of the gut microbiota. Obligate
anaerobic bacteria belonging to the classes Bacteroidia (phylum
Bacteroidetes) and Clostridia (phylum Firmicutes) break down
complex carbohydrates from fiber or mucus, which results in
the release of metabolic end products, including hydrogen;
organic acids, such as lactate and succinate; alcohols, such as
1,2 propanediol; and short-chain fatty acids (SCFAs), such as
formate, acetate, propionate, and butyrate (Figure 2) (reviewed
in Fischbach and Sonnenburg, 2011). Hydrogen is consumed
by obligate anaerobic sulfate-reducing bacteria of the family
Desulfovibrionaceae (phylum Proteobacteria), a process yielding
the metabolite hydrogen sulfide (H2S) (Deplancke et al., 2000;
Fite et al., 2004; Zinkevich and Beech, 2000). Members of
the phyla Bacteroidetes, Firmicutes, and Fusobacteria degrade
indigestible proteins, such as gluten, into amino acids to support
Figure 1. Microbial Products Induce
Mucosal Barrier Functions
Concomitant activation of TLR5 during presenta-
tion of flagellin by antigen-presenting cells (APCs)
renders flagellin a dominant B cell antigen.
Flagellin-specific immunoglobulin A (IgA) helps
control motile bacteria in the gut lumen. Indole
derivatives (tryptamine, indole 3-acetate and
indole) are produced by the gut microbiota during
the breakdown of indigestible proteins. These
metabolites induce the release of IL-22 by acti-
vating the aryl hydrocarbon receptor (AHR) on
host cells. IL-22 stimulates epithelial cells to
release antimicrobial proteins (such as RegIIIb,
RegIIIg, lipocalin-2, and calprotectin) that help
control luminal bacteria.
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tryptophan by facultative anaerobic bacteria of the class Bacilli
(phylum Firmicutes) yields a number of metabolites, such as
indole, indole 3-acetate, and tryptamine, which accumulate in
the intestine (Figure 1) (Jin et al., 2014; Zelante et al., 2013).
Furthermore, dietary phospholipids are broken down by the
microbiota anaerobically to yield the metabolites ethanolamine
and trimethyl amine (TMA) (de la Huerga and Popper, 1951;
Oresic et al., 2009; Tang et al., 2013). These examples illustrate
that the combined metabolic activities of gut-associated micro-
bial communities lead to the accumulation of a variety of micro-
biota-derived metabolites in the lumen of the distal gut. We will
discuss below how many of these metabolites influence host
physiology.
Nursing the Host: Microbiota-Derived Butyrate
Energizes Colonocytes
One of the beneficial properties of a balanced gut microbiota
is to provide nutrition for the host. A good example is the
mitochondrial oxidation of microbiota-derived butyrate into
carbon dioxide, which represents the primary energy source
for colonocytes that comprise the colonic epithelium (Figure 2)
(Donohoe et al., 2012). Exposure to SCFAs, such as butyrate,
triggers profound changes in epithelial gene expression in vitro
(Basson et al., 2000; Sanderson, 2004), which are mediated at
least in part through the SCFA sensor PPAR-g (peroxisome
proliferator activated receptor-g) (Alex et al., 2013). The
absence of SCFAs in the large bowel of germ-free mice leads
to major changes in the energy metabolism of colonocytes,
which switch from oxidizing butyrate to fermenting glucose
into lactate (Donohoe et al., 2012). Thus, microbiota-derived
metabolites can have a marked influence on the energy meta-
bolism of host cells. An increased concentration of fecal
SCFAs in obese individuals compared to subjects with normal
weight suggests that concentrations of these metabolites
might be relevant for the development of metabolic syndrome
(Schwiertz et al., 2010).Cell Host & Microbe 16Fortifying the Barrier: Microbial
Products Help Control
the Community
Some products of the gut microbiota
elicit immune responses that are aimed
at maintaining mucosal barrier integrityby controlling luminal microbes. For instance, flagellin, the
structural protein subunit of the flagellar filament, is a MAMP
recognized by Toll-like receptor 5 (TLR5) (Hayashi et al., 2001).
Its TLR5 agonist activity makes flagellin a dominant antigen for
CD4 T cells and B cells (Atif et al., 2014; Cullender et al., 2013).
Although it remains unclear how flagellin crosses the epithelial
barrier, flagellin-specific immunoglobulin reduces bacterial
motility in the gut lumen, thereby strengthening epithelial barrier
function (Figure 1) (Cullender et al., 2013).
Probiotic Lactobacillus species produce tryptophan metabo-
lites, such as indole, indole 3-acetate, and tryptamine (Zelante
et al., 2013), which are ligands of the aryl hydrocarbon receptor
(AHR) expressed on T helper type 17 (TH17) cells, innate
lymphoid cells, and dendritic cells (Heath-Pagliuso et al., 1998;
Miller, 1997). TH17 responses are important for the control of
luminal pathogens (Zheng et al., 2008). AHR activation leads to
the production of interleukin 22 (IL-22), a TH17 cytokine that
acts on epithelial cells to induce the luminal release of anti-
microbial proteins, such as lipocalin-2, calprotectin, RegIII-b
(regenerating islet-derived protein 3 beta), and RegIII-g (Figure 1)
(Fukumoto et al., 2014; Monteleone et al., 2011; Zelante et al.,
2013). Production of IL-22 in the intestine can also be elicited
by bacterial flagellin through a TLR5-dependent mechanism
(Kinnebrew et al., 2010). The epithelial release of antimicrobial
proteins can alter themicrobiota composition by favoring growth
of bacteria that express the corresponding resistance mecha-
nisms (Behnsen et al., 2014; Raffatellu et al., 2009). Furthermore,
growth of bacteria that are susceptible to these antimicrobial
responses is reduced. Through this mechanism, the IL-22-
induced epithelial release of antimicrobial proteins protects
the mucosal surface from the attaching and effacing pathogen
Citrobacter rodentium (phylum Proteobacteria) (Zheng et al.,
2008); reduces colonization of opportunistic pathogens, such
as Candida albicans (a fungus belonging to the phylum Ascomy-
cota) (Zelante et al., 2013) or vancomycin resistant Enterococcus
species (phylum Firmicutes, class Bacilli) (Kinnebrew et al.,
2010); and helps control the growth of pathobionts, such as, August 13, 2014 ª2014 Elsevier Inc. 157
Figure 2. Maintenance of Immune
Homeostasis by Microbiota-Derived
Metabolites
Digestion of dietary fiber leads to an accumulation
in the gut lumen of microbiota-derivedmetabolites
that have anti-inflammatory properties. Activation
of the SCFA receptor PPAR-g inhibits proin-
flammatory responses by inhibiting NF-kB acti-
vation. SCFAs cause an expansion of regulatory
T cells through mechanisms that depend on
SCFA receptors GPR43 and GPR109A. In turn,
regulatory T cells maintain gut homeostasis
by resolving inflammation through inhibition of
effector T cell function and increasing production
of IL-10. SCFAs can enter the circulation and
enhance the generation of APC precursors in
the bone marrow through a GPR41-dependent
mechanism. After seeding the lung, APCs gener-
ated through this process exhibit a reduced
ability to promote T helper type 2 (TH2) cell effector
function, thereby conferring protection from
allergic airway inflammation.
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Clostridia) (Qiu et al., 2013).
SFBs are nonculturable obligate anaerobic bacteria that live
in tight association with epithelial cells in the murine intestine.
Colonization with SFBs induces a robust TH17 response, which
clearly distinguishes these pathobionts from other, more benign
members within the community (Gaboriau-Routhiau et al., 2009;
Ivanov et al., 2009; Salzman et al., 2010). Although SFBs are not
part of the human gut microbiota, we may engage in a similar
relationship with Helicobacter pylori (phylum Proteobacteria), a
pathogen entering the stomach early in life followed by stable
colonization that continues throughout adulthood. H. pylori
colonization influences the development of our immune system,
as illustrated by its protective role in esophageal adenocarci-
noma (Blaser, 2008).
Maintaining Balance: Metabolites Preserve Gut
Immune Homeostasis
While the presence of a balanced gut microbiota can help
to fortify the epithelial barrier, arguably the most important
characteristic of a balanced microbial community is its ability
to maintain immune homeostasis. One mechanism by which
the gut microbiota maintains immune homeostasis was gleaned
from studies on Bacteroides fragilis. B. fragilis produces surface158 Cell Host & Microbe 16, August 13, 2014 ª2014 Elsevier Inc.polysaccharide A, a MAMP that stimu-
lates TLR2 expressed on regulatory
T cells (Round et al., 2011), thereby
inducing their activation and subsequent
suppression of inflammatory responses
in the intestine (Mazmanian et al., 2008).
However, polysaccharide A production
is not a trait that is widely distributed
amongmembers of the class Bacteroidia,
which predicts the existence of additional
mechanisms that are more broadly
conserved evolutionarily.
One such mechanism is mediated by
SCFAs, metabolites produced by many
of the phylogenetic groupings repre-sented within gut-associated microbial communities. The host
can detect and respond to the presence of SCFAs using the
intracellular receptor PPAR-g, the surface located G protein-
coupled receptor 43 (GPR43, also known as free fatty acid re-
ceptor 2 [FFAR2]), GPR41 (FFAR3), and the butyrate receptor
GPR109A (also known as hydroxycarboxylic acid receptor 1
[HAC2] or HM74A) (Alex et al., 2013; Brown et al., 2003;
Le Poul et al., 2003; Taggart et al., 2005). Furthermore, SCFAs
inhibit the activities of histone deacetylases (HDACs) in host
cells (Siavoshian et al., 2000). The anti-inflammatory properties
of SCFAs, most importantly acetate, propionate, and butyrate,
have been long recognized (reviewed in Al-Lahham et al.,
2010; Tan et al., 2014). For example, after surgical interventions
that require a diversion of the fecal stream, concentrations of
SCFAs drop in segments of the colorectum, resulting in diversion
colitis, which can be brought into remission by irrigation with
SCFA solution (Harig et al., 1989).
SCFAs can suppress inflammation through several distinct
mechanisms. SCFAs can suppress inflammation through a
GPR41-dependent pathway, although the underlying mecha-
nism has not been fully resolved (Trompette et al., 2014).
Butyrate downregulates lipopolysaccharide-induced responses
in intestinal macrophages by inhibiting HDACs in vitro; however,
this mechanism does not influence the severity of chemically
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by SCFAs can reduce host inflammatory responses in vitro by
promoting nuclear export of the NF-kB (nuclear factor kappa-
light-chain-enhancer of activated B cells) subunit RelA (Figure 2)
(Kelly et al., 2004). SCFA can promote the resolution of inflam-
mation in a mouse model of chemically induced colitis by acti-
vating GPR43 (Maslowski et al., 2009). Here, the underlying
mechanism is a stimulation of GPR43 on regulatory T cells,
which causes this cell population to expand in the colon, thereby
limiting the proliferation of effector CD4+ T cells and increasing
the expression of the anti-inflammatory cytokine IL-10 (Arpaia
et al., 2013; Atarashi et al., 2011; Furusawa et al., 2013; Smith
et al., 2013). Butyrate can also induce IL-10 production by anti-
gen-presenting cells (APCs) (Millard et al., 2002; Wang et al.,
2008). The mechanism behind this activity of butyrate is an
activation of GPR109A expressed on APCs in the colon, which
induces the release of IL-10, a process that promotes the matu-
ration of naive T cells into regulatory T cells (Singh et al., 2014).
Mice deficient for Niacr1, the gene encoding GPR109A, exhibit
increased susceptibility to chemically induced colitis (Singh
et al., 2014). Tryptophan metabolites might exhibit properties
that are similar to those of SCFAs, because activation of AHR
also reduces the severity of inflammation in a mouse model of
hapten-induced colitis by inducing an expansion of regulatory
T cells (Benson and Shepherd, 2011).
The picture emerging from above studies is that microbiota-
derived metabolites display prominent anti-inflammatory prop-
erties that are important for maintaining intestinal immune
homeostasis. Conditions that lead to a drop in the concentration
of microbiota-derived metabolites would thus be predicted to
disrupt immune homeostasis and predispose to inflammatory
diseases.
Side Effects: Antibiotics Deplete Microbiota-Derived
Metabolites
Antibiotic treatment results in a severe disruption of the gut mi-
crobiota of humans, which is characterized by a decrease in
both the taxonomic richness and diversity of the community
(Dethlefsen et al., 2008). Within 4 weeks after withdrawal of anti-
biotics the microbiota returns to an overall composition that
resembles the pretreatment state, although some changes in
the community can persist for longer periods of time (Dethlefsen
et al., 2008; Dethlefsen and Relman, 2011; Jernberg et al., 2007).
It is perhaps not surprising that the rapid loss in diversity of the
gut microbiota observed after antibiotic treatment has profound
effects on its combined metabolic activities and products.
Treatment of mice with a combination of metronidazole,
neomycin, and vancomycin lowers intestinal expression of the
antimicrobial peptide RegIII-g, suggesting that the ability of the
gut-associated microbial community to fortify barrier functions
can be impaired by antibiotic treatment (Brandl et al., 2008).
There is direct evidence to suggest that changes in the compo-
sition of the gut microbiota that are associated with antibiotic
treatment can lead to a drop in the concentrations of some
microbiota-derived metabolites. For example, dietary phospha-
tidylcholine is metabolized by the gut microbiota to generate
TMA, which is absorbed and then oxidized in host tissue to
form trimethyl amine oxide (TMAO). Measurements of TMAO
concentrations in human plasma and urine reveal a markeddecline after the administration of antibiotics and a succeeding
increase after withdrawal of antibiotics (Tang et al., 2013). Anti-
biotics also lower the concentrations of metabolites derived
from complex carbohydrate fermentation, because treatment
of mice with streptomycin, metronidazole, or vancomycin re-
duces SCFA concentrations in the cecum (Garner et al., 2009;
Meynell, 1963; Smith et al., 2013). Similarly, volunteers treated
orally with metronidazole, vancomycin, or bacitracin excrete
significantly reduced levels of fecal SCFAs (Høverstad et al.,
1986; Lewis et al., 2005). Oral doxycycline, cotrimoxazole,
nalidixic acid, or ofloxacin treatment does not produce this
effect in volunteers, which illustrates that not all antibiotics
reduce the metabolic activities of gut-associated microbial
communities to the same extent, perhaps due to differences in
their pharmacokinetics or to factors that remain to be worked
out. Nonetheless, it is clear from the above data that at least
some antibiotics cause a disruption of the gut microbiota that
is severe enough to significantly reduce the concentrations of
microbiota-derived metabolites. We will discuss below how
this side effect of antibiotic treatment can have several adverse
consequences for the host.
Undesired Consequences: Metabolite Depletion
Disrupts Gut Homeostasis
Disruption of the gutmicrobiota by vancomycin treatment lowers
intestinal SCFA concentrations, thereby reducing stimulation of
GPR43 on regulatory T cells, which leads to a contraction of
this cell population in the colonicmucosa, but not in other organs
(Atarashi et al., 2011; Smith et al., 2013). However, the numbers
of regulatory T cells in the colon remain unchanged when
mice are treated with a combination of vancomycin and SCFAs
(Smith et al., 2013). These data suggest that antibiotic treatment
can lower the numbers of regulatory colonic T cells by reducing
the concentration of SCFAs in the distal gut.
An antibody-mediated depletion of regulatory T cells does not
trigger overt intestinal inflammation in mice, but it increases the
severity of chemically induced colitis (Boehm et al., 2012). An
antibiotic-induced lowering of intestinal SCFA concentrations
and consequent reduction in the numbers or regulatory T cells
is therefore predicted to render the host more susceptible to
colitis. In line with this prediction, antibiotic treatment enhances
the severity of chemically induced colitis in mice (Rakoff-
Nahoum et al., 2004; Singh et al., 2014; Spees et al., 2013b).
Similarly, the severity of colitis caused by enteric pathogens,
such as Citrobacter rodentium or Salmonella enterica serovar
Typhimurium (family Enterobacteriaceae, phylum Proteobacte-
ria), is enhanced in mice treated with streptomycin, vancomycin,
or metronidazole (Barthel et al., 2003; Spees et al., 2013b; Wlo-
darska et al., 2011). Consistent with a mechanism that depends
on a disruption of the community of SFCA producers, the
enhanced severity of S. enterica-induced colitis after antibiotic
treatment is independent of pathogen colonization, but corre-
lates with differences in the composition of the gut microbiota
(Ferreira et al., 2011) and reduced concentrations of SCFAs in
the large bowel (Garner et al., 2009).
Antibiotic treatment also lowers ‘‘colonization resistance’’
against enteric pathogens belonging to the family Entero-
bacteriaceae. The concept that the gut microbiota confers
‘‘colonization resistance’’ against Enterobacteriaceae was firstCell Host & Microbe 16, August 13, 2014 ª2014 Elsevier Inc. 159
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treatment with streptomycin greatly enhances the ability of
S. enterica or Escherichia coli to colonize the large bowel of
mice (Bohnhoff et al., 1954; Saito, 1961a, 1961b). Early work
on the underlying mechanism revealed that streptomycin treat-
ment lowers the concentration of SCFAs and increases the
redox potential in the cecum to conditions that approximate
an aerobic broth culture (Meynell, 1963). More recent results
show that treatment with antibiotics leads to a subtle elevation
of some inflammatory markers in the intestinal mucosa (Spees
et al., 2013b; Wlodarska et al., 2011), which might be a conse-
quence of lowering the concentrations of microbota-derived
metabolites that possess anti-inflammatory properties, such
as SCFAs (Garner et al., 2009; Høverstad et al., 1986; Lewis
et al., 2005; Meynell, 1963; Smith et al., 2013). For instance,
streptomycin treatment of mice markedly increases cecal
expression of inducible nitric oxide synthase (iNOS) encoded
by the NOS2 gene (Spees et al., 2013b), the expression of
which is suppressed in human colonocytes by the SCFA
sensor PPAR-g (Marion-Letellier et al., 2008). Furthermore,
mild inflammatory infiltrates of neutrophils, inflammatory mono-
cytes, and natural killer cells are observed in the intestinal
mucosa of mice treated with streptomycin or metronidazole
(Spees et al., 2013b; Wlodarska et al., 2011). In humans,
repeated courses of antibiotics can lead to the development
of irritable bowel syndrome (IBS), a condition characterized
by low-level intestinal inflammation, diarrhea, lower concentra-
tions of fecal SCFAs (Kopecny and Simunek, 2002; Treem
et al., 1996), and an increased abundance of Enterobacteria-
ceae in the fecal microbial population (Carroll et al., 2012;
Ma¨tto¨ et al., 2005).
The observation that antibiotic treatment can induce iNOS
expression (Spees et al., 2013b)might help explain the increased
redox potential in the cecum of streptomycin-treated mice first
observed in 1963 (Meynell, 1963). Nitric oxide generated by
iNOS can react with superoxide produced by epithelial NADPH
oxidases to give rise to peroxynitrite, which can be further
converted to nitrate (Szabo´ et al., 2007). Nitrate is an excellent
respiratory electron acceptor, because the redox potential of
the nitrate/nitrite redox couple (E = 433 mV) is second only to
that of the oxygen/water redox couple (E = 818 mV) (Thauer
et al., 1977). Nitrate respiration enhances growth of E. coli in
the large bowel of streptomycin-treated mice (Jones et al.,
2011) and in mice with chemically induced colitis (Winter et al.,
2013a), but not in untreated mice (Spees et al., 2013b). Further-
more, the fitness advantage conferred upon E. coli by nitrate
respiration is abrogated in streptomycin-treated NOS2-deficient
mice, suggesting that nitrate in the gut lumen after antibiotic
treatment is host derived (Spees et al., 2013b).
The evidence reviewed above raises the possibility that anti-
biotics can disrupt immune homeostasis by disrupting the com-
munity of SCFA producers, in turn increasing the inflammatory
tone of the intestinal mucosa. This low degree of inflammation
might lead to an enhanced susceptibility to colitis and is at
least in part responsible for reducing ‘‘colonization resistance’’
against Enterobacteriaceae (Spees et al., 2013a). Enterobacter-
iaceae benefit from low-level intestinal inflammation because
byproducts of the inflammatory host response, such as nitrate,
can selectively boost the growth of these facultative anaerobic160 Cell Host & Microbe 16, August 13, 2014 ª2014 Elsevier Inc.bacteria in the large bowel (Lopez et al., 2012; Spees et al.,
2013b; Winter et al., 2013b). For example, an analysis of 2,476
genomes representing all phylogenetic groupings found within
the gutmicrobiota suggests that sequences predicted to encode
nitrate reductase activity are present at the highest frequency
within members of the Enterobacteriaceae (Winter and Ba¨umler,
2014). Thus, the generation of host-derived nitrate after antibiotic
treatment might selectively boost the growth of Enterobacteria-
ceae simply because its members are more likely to encode
the enzymes to utilize this electron acceptor.
Hidden Costs: Beyond the Hygiene Hypothesis
While it may be unsurprising that a severe disruption of gut-asso-
ciated microbial communities by antibiotics influences immune
homeostasis and pathogen susceptibility in the gut, it is less
obvious that it also impacts immune responses in distal organs,
such as the airways. An increase in allergies observed since
the second half of the 20th century has been attributed by the
‘‘hygiene hypothesis’’ to decreased exposure to sporadic infec-
tions in early childhood (Strachan, 1989). The progressive disap-
pearance of H. pylori in high-income countries over the course
of the 20th century is inversely correlated to childhood asthma
(Chen and Blaser, 2008; Reibman et al., 2008), which led to the
advancement of the ‘‘disappearing microbiota hypothesis’’ for
explaining the rise in allergies by a lack of continued exposure
to H. pylori during childhood (Blaser, 2008). These hypotheses
suggest that sporadic exposure (‘‘hygiene hypothesis’’) or
continued exposure (‘‘disappearing microbiota hypothesis’’) to
pathogens in early childhood has a protective role against
allergic diseases by influencing the development of the neo-
nate’s immune system. However, recent evidence suggests
that in addition to pathogen exposure, the continued exposure
to metabolites produced by the commensal gut microbiota
plays a protective role in preventing allergic airways disease
(Bjorksten, 2009; Isolauri et al., 2009; Shreiner et al., 2008).
One reason for such distal effects is that some microbiota-
derived metabolites enter the circulation and influence cells
that are located within peripheral tissues. For example, fermen-
tation of complex carbohydrates by the gut microbiota increases
systemic levels of SCFAs, which in turn influence dendritic cell
hematopoiesis and functionality by a mechanism that depends
on GPR41, a SCFA receptor expressed on the surface of host
cells (Trompette et al., 2014). Stimulation of GPR41 with propio-
nate does not lead to an accumulation of regulatory T cells, but
protects against allergic inflammation in the lung through a
mechanism that involves decreased activation of lung dendritic
cells (Trompette et al., 2014) (Figure 2). The relevance of this
observation is highlighted by clinical studies documenting an
increased risk for developing allergic asthma after exposure to
antibiotics early in life (Marra et al., 2009; Martel et al., 2009;
Murk et al., 2011). Furthermore, low fecal SCFA levels in children
are associated with allergy (Sandin et al., 2009). A vancomycin-
mediated disruption of the community of SCFA producers in
neonatal mice, but not in adult mice, enhances subsequent sus-
ceptibility to allergic asthma (Russell et al., 2012), suggesting
that an antibiotic-mediated disruption of the gut microbiota
might be most consequential during the developmental period.
While the ‘‘hygiene hypothesis’’ and the ‘‘disappearing
microbiota hypothesis’’ propose exposure to pathogens as a
Cell Host & Microbe
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provide evidence for a second mechanism that involves expo-
sure to metabolites produced by commensal, nonpathogenic
gut microbes early in life. The terms ‘‘microbial deprivation
hypothesis’’ (Bjorksten, 2009) and ‘‘microflora hypothesis’’
(Shreiner et al., 2008) have been advanced to describe the
idea that continued exposure to a balanced gut microbiota
during childhood, more than sporadic infections, is an important
factor for the prevention of allergy. Antibiotics can disrupt a
continued exposure to microbiota-derived metabolites, thereby
increasing susceptibility to allergies.
In conclusion, microbes inhabiting our gastrointestinal tract
during the first years of life shape our physiology and may
have lifelong influences on our immune system. A combination
of an increasing childhood exposure to antibiotics starting
in the second half of the 20th century and a progressive disap-
pearance of H. pylori throughout the last century impair immune
education, thereby contributing to the concomitant rise in
allergies observed in high-income countries.Conclusions
Our lifelong association with a large microbial community inhab-
iting our intestine provides local as well as systemic benefits. The
combined metabolic activities of the gut microbiota promote
host nutrition, mucosal barrier function, gut immune homeosta-
sis, ‘‘colonization resistance,’’ and immune education. Recent
research is beginning to illuminate the consequences of
perturbing this homeostasis, for example by depleting micro-
biota-derived metabolites during antibiotic therapy. A better
understanding of these microbe-host interactions will aid in the
development of strategies to prevent undesired side effects
of antibiotic therapy and improve human health.ACKNOWLEDGMENTS
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